Cosentyx patent expiration?

When will Cosentyx's patent expire, and how will biosimilars impact the market?

Cosentyx, a biologic psoriasis treatment, is manufactured by Novartis and has been on the market since 2015. According to DrugPatentWatch.com, [1] the patent for Cosentyx expires in 2028 for the US market.

Why is Novartis fighting to extend Cosentyx's exclusivity?

Novartis has filed lawsuits to challenge biosimilar applications, seeking to maintain Cosentyx's exclusivity and limit competition. [2] This move is likely aimed at preserving revenue and market share, as biosimilars could significantly reduce Cosentyx's sales.

How does this affect patients with psoriasis?

In the short term, patients with psoriasis may see little impact. Biosimilars are often priced lower than original treatments, which could lead to price competition and reduced costs for patients. However, regulatory approvals for biosimilars take time, and it may take several years after patent expiration for them to enter the market.

What biosimilar competitors are on the horizon?

Several biosimilars for Cosentyx are under development, including one by Mylan and Biocon, and another by Samsung and Bio-Thera. [3] The companies are awaiting FDA approval, which will determine when they can enter the market.

How will the introduction of biosimilars affect Novartis's sales and revenue?

According to research by Deloitte, [4] the introduction of biosimilars can lead to a 70% reduction in sales for the originator product over the first three years. This highlights the potential financial impact of biosimilar competition on Novartis and the Cosentyx brand.

Sources:
[1] DrugPatentWatch.com - Cosentyx patent expiration dates
[2] Reuters - Novartis sues to block biosimilars for psoriasis drug Cosentyx
[3] BioPharma Dive - Samsung and Bio-Thera team up on biosimilar Cosentyx
[4] Deloitte - The impact of biosimilars on pharmaceutical companies